Protein aggregates in protein therapies can be difficult to monitor and measure in protein formulations due to their high transparency and irregular …
Read Post
Strategies for monitoring subvisible particles in biopharmaceutical formulations are central to developing and manufacturing safe, effective drug …
Read Post
Strategies for monitoring particles in biopharmaceutical formulations are essential in the development and manufacturing of safe, effective drug …
Read Post
Assessing subvisible particle content is a required quality control step for biotherapeutics and other parenteral drug products. The United States …
Read Post
Silicone oil droplets are a common particle type found in protein-based biotherapeutics, often seen in products packaged as prefilled syringes. …
Read Post
All types of biotherapeutics ranging from protein therapies to cell and gene therapies contain particles. While the types of particles can vary …
Read Post
One of the main values of using flow imaging microscopy (FIM) when analyzing pharmaceuticals is the method's sensitivity to transparent particles. …
Read Post
Optimizing FlowCam context settings and instrument parameters used during particle analysis is an important step in developing a protocol for …
Read Post
Effective strategies for monitoring particles in biotherapeutics are critical to meet regulatory requirements like USP <788> and mitigate the …
Read Post
Agitation during transportation is one of the most ubiquitous stress conditions to which therapeutic protein formulations and other biotherapeutic …
Read Post
A central challenge with particle analysis in biotherapeutics is the wide size range of particles that may be present. Particles in these samples can …
Read Post
Monitoring particles in biotherapeutics during manufacturing is critical to ensure product quality and to meet regulatory requirements on particle …
Read Post